Substances in the form of weak acid salts have been found to be problematic for dissolution testing. Their absorption can start only aft er they are turned into the form of an acid following the gastric passage although they were administered in the form of a salt. Due to poor solubility, they cannot be tested in acidic gastric environment for a biased dissolution profi le. The biphasic dissolution method is promising for overcoming this obstacle. Tablets with warfarin clathrate sodium salt in two concentrations and two diff erent particle size distributions were tested as a suitable model for fi nding the medium and process conditions of dissolution. The dissolution method based on the use of the upper organic layer (1-octanol) and the lower aqueous layer (0.1 mol L -1 HCl) was found suitable and discriminatory for tablets containing active substances in the form of salts of weak acids. The method also refl ects physical diff erences in the quality of used substances.
Dissolution methods for oral drugs containing an active substance in the form of a weak acid salt have to refl ect their specifi c physicochemical and biological properties. In acidic gastric environment, these substance turn into the acid form, which is oft en poorly soluble. Therefore, dissolution testing in simulated gastric fl uid is out of the question. The warfarin sodium tablets USP monograph (warfarin is a typical example of the above mentioned drugs) requires only water as a dissolution medium (1) . This method, which is neither biorelevant nor discriminatory because of very good solubility of warfarin sodium in water, contains only one sampling point. This does not allow adequate evaluation of any changes in the quality of the active substance or the impact of diff erent active substance concentrations in tablets of diff erent strengths on the dissolution profi le. However, a suitable discriminatory dissolution method can unveil diff erences in the active substance liberation with respect to its quality and concentration under conditions close to those present in an organism and is thus suitable for estimating in vitro -in vivo correlation (IVIVC) (2) .
Biphasic dissolution is a suitable dissolution method for drugs in the form of weak acid salts, combining the acidic gastric environment and lipophilic character of cell membranes through which the drug is absorbed. Having partially dissolved in the aqueous acidic phase, the active substance in the form of a weak acid may move by diff usion to the organic layer; fi nally, a balanced state dependent on the partition coeffi cient is achieved. Biphasic dissolution system is simple, easy to implement and uses commonly available equipment. The advantage of this system lies in its single-step likeness to in vivo liberation, dissolution and absorption of active substances in the gastrointestinal tract (3) . A commercial automated equipment for biphasic dissolution testing has been recently introduced, allowing easy, routine use of this method (4) . The aim of this study was to identify suitable conditions for testing substances in the form of weak acid salts, using a model example of tablets containing warfarin sodium in two concentrations and two particle size distributions. The resulting dissolution profi le should be similar as much as possible to the in vivo liberation. Furthermore, the proposed method was evaluated to fi nd if it is discriminatory and able to detect changes in both the content and quality of active pharmaceutical ingredients (API).
EXPERIMENTAL

Materials
Warfarin standard, 1-octanol, methanol and hydrochloric acid were all obtained from Sigma Aldrich (UK). All materials were of analytical grade and used without further purifi cation. Deionized water was prepared in house. The composition of tested tablets and used raw material is given in Table I . a D x -x is % of measured particles that are smaller than this size (μm).
Di-cafos -calcium hydrogen phosphate, Avicel PH 101 -microcrystalline cellulose, Ac-Di-Sol -sodium crosscarmellose
Manufacturing of tablets
In order to design the biphasic dissolution method, tablets containing 1 mg or 10 mg of API were manufactured by direct compression from a single tablett ing blend. All manufactured batches met the requirements of valid USP and EP monographs on friability, hardness and disintegration. Two batches of each strength were prepared, diff ering in particle size distribution of API, i.e., batches with 1 or 10 mg of API of narrow particle size distribution (batches W1A and W10A), respectively, and of wide particle size distribution (batches W1B and W10B). The composition of tablett ing blends and the manufacturing process are based on the VFU patent (5) and literature (6) .
The composition of the blends and some physicochemical properties of raw materials are listed in Table I . All constituents were sieved through a 250-μm sieve. All constituents without magnesium stearate were mixed for 10 minutes, then magnesium stearate was added and another 5 minutes of mixing followed. A Turbula (T2C, Switzerland) homogenizer was used, speed 40 rpm. The mass of a batch was 500.0 g.
Tablets containing 1 mg of API weighed 54.2 mg. They were fl at with a 5-mm diameter and hardness about 100 N. Tablets containing 10 mg of API weighed 542.0 mg; they were fl at with a 10-mm diameter and hardness about 100 N. All batches were produced using an eccentric press (Korsch EK0, Germany).
Dissolution test
The tests were carried out on a SOTAX (AT 7 Donau Lab, Switzerland). Biphasic dissolution was performed using 900 mL of 0.1 mol L -1 HCl and 70.0 g of 1-octanol maintained at 37.0 ± 0.5 °C, using USP paddles at a rotation speed of 50 rpm. One mL of dissolution medium (water and organic phase) was withdrawn aft er 1, 2, 4 and 8 hours of dissolution. Dissolution of tablets in water was done according to the USP monograph using 900 mL of water maintained at 37 °C and paddles rotating at 50 rpm (1). Sampling points were at 10, 20, 30 and 60 min. Samples from all dissolution tests were fi ltered using 0.45-μm syringe fi lters; warfarin content was then analyzed by liquid chromatography. For each sampling point, mean and standard deviations were calculated.
Chromatographic analysis
To measure warfarin content in samples, we used high performance liquid chromatography and adhered to the published method (6). Quantifi cation followed the calibration curve, which expressed the relation between the peak area and warfarin concentration (samples from organic phase) or warfarin clathrate sodium salt concentration (samples from aqueous phase).
Statistical analysis
To compare the dissolution profi les of tablet batches, the diff erence factor f 1 and the similarity factor f 2 were calculated. Diff erence and similarity factors were determined for samples W1A-W10A, W1B-W10B to fi nd the infl uence of warfarin content in tablets (1 mg or 10 mg) and for samples W1A-W1B, W10A-W10B to examine the eff ect of warfarin particle size distribution (mean particle size 4.8 or 22.5 μm).
RESULTS AND DISCUSSION
In this study, warfarin sodium was chosen as a model drug for the development of a biphasic dissolution method because of its physicochemical properties. Warfarin is used as sodium salt and as free acid; it is acidic (pK a = 5.0) and poorly soluble in water. In order to develop a discriminatory dissolution method suitable for evaluation of active substances (weak acids), tablets containing warfarin clathrate sodium salt were prepared (composition in Table I ) choosing strengths of commercially available warfarin (1 mg and 10 mg) . Considering the fact that physical properties of API have an impact on warfarin pharmacokinetics (7), diff erent particle size distribution of the active substance was chosen as a qualitative parameter (D 50 = 4.8 or 22.5 μm). These two variables were chosen because the optimal dissolution method should identify changes in product quality while being suitable for the whole range of marketed strengths. Manufactured tablets were tested according to EP and USP quality requirements for friability, hardness and disintegration. The results of they were similar, and as these tests were run according to pharmacopoeial monographs, they prove that physical parameters will not have a signifi cant impact on the diff erences in dissolution profi les. The USP dissolution method was used to evaluate tablets with diff erent warfarin contents and particle size distribution. Fig. 1 shows that aft er 10 minutes, almost all active substance was liberated in all batches and no diff erences between samples could be observed. This method is neither discriminatory nor biorelevant.
The conditions of a dissolution method suitable for dosage forms containing active substances in the form of salts of weak acids should simulate real conditions in the gastrointestinal tract as much as possible. Therefore, we chose 0.1 mol L -1 hydrochloric acid for the aqueous phase (simulation of gastric environment) and 1-octanol for the organic phase (simulation of transport through the biological barrier). Further dissolution conditions such as the volume of aqueous phase, temperature and paddle rotations follow dissolution requirements as given in the Warfarin Sodium Tablets USP monograph (1). As small as possible volume of organic phase was chosen to allow easy sampling and meeting "sink conditions" (the concentration of saturated solution of warfarin in 1-octanol is fi ve times higher than the concentration of warfarin solution in 1-octanol obtained by dissolving completely the dose contained in one tablet) during the dissolution process of both tested strengths.
At fi rst sight, the dissolution profi les obtained by biphasic and pharmacopoeial methods (Fig. 1) state clearly that dissolution profi les in the 1-octanol phase do diff er whereas those acquired by the USP dissolution method do not. Using the similarity factor f 2 and the diff erence factor f 1 for statistical evaluation of the likeness of these profi les (Table II) , we found out that the dissolution profi les of tablets with diff erent strengths diff er statistically signifi cantly only in the case of API with wide particle size distribution. Dissolution profi les of tablets with diff erent strengths and API with narrow particle size distribution are statistically diff erent when using f 1 for comparison (f 1 > 15.0). When using f 2 , there was no statistically signifi cant diff erence between these profi les; however, f 2 was close to the critical value of 50. Under chosen conditions of biphasic dissolution, the method is discriminatory with respect to the content of active substance in the tablet. Statistical comparison of the dissolution profi les of tablets with the same strength and diff erent particle size distribution of API has proven that these dissolution profi les are similar (according to both f 2 and f 1 ). Nevertheless, the actual values of f 2 and f 1 show that the impact of particle size distribution on the dissolution profi le is higher in tablets with higher API content (f 2 = 54.5, f 1 = 11.7) than in tablets with lower content of API (f 2 = 76.7, f 1 = 4.3). Diff erent contents of API in tablets led to more pronounced diff erences in dissolution profi les than physical properties, i.e., particle size distribution of the active substance.
In the course of biphasic dissolution testing, the concentration of API in the aqueous phase (0.1 mol L -1 HCl) was measured as well. In all batches, the content of API in the aqueous phase was lower than 15 % (Fig. 1) . During the dissolution test, the non-ionized active substance is moving continually to the lipophilic phase, similarly to the process of absorption in the gastrointestinal tract. This fi nding is in accord with the requirements of a biorelevant dissolution method.
The described biphasic dissolution method meets the requirements for the calculation and use of f 2 and f 1 factors with respect to the number of sampling points (60, 120, 240 and 480 minutes), RSD values (lower than 20 % at the fi rst point, lower than 10 % at subsequent points, Table III) , and only one point lies outside the line of 85 % of dissolved active substance. Owing to the character of the dissolution method, which takes into account physi- ological conditions, this method meets general requirements for the design of dissolution methods. This method can be considered biorelevant, since 50 % of active substance is released in 120-240 minutes, corresponding to the peak concentration of warfarin in blood plasma in vivo, i.e., 108-222 min aft er oral administration (7). The method seems to be suitable for IVIVC (8) .
CONCLUSIONS
A biphasic discriminatory dissolution method was designed based on using the upper organic layer (1-octanol) and the lower aqueous layer (0.1 mol L -1 HCl), which simulates the gastric environment. The method seems to be suitable for dosage forms containing active substances in the form of salts of weak acids, where dissolution testing in simulated gastric fl uid is inconvenient. The designed conditions of biphasic dissolution testing are suffi cient to meet the requirements for f 1 and f 2 calculation. The method is suitable for statistical comparison of the dissolution profi les of tablets with diff erent quantitative or qualitative parameters and method for the development, clinical evaluation, as well as routine quality control release evaluation. As the equipment for routine biphasic dissolution measurement is already available, this method could play a major role in quality assurance and control as well as help decrease development costs for both innovative and generic pharmaceutical industry.
